LivaNova Publishes 24-Month Data On Generalized Tonic-Clonic Seizures In People With DRE From CORE-VNS Three-Year Study In Epilepsia

This is the latest prospective evaluation of VNS Therapy in generalized tonic-clonic seizures

Findings include 77% median seizure reduction and 43% of participants reporting seizure freedom at 24-month visits

LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced that 24-month data on generalized tonic-clonic (GTC) seizures in people with drug-resistant epilepsy (DRE) from the CORE-VNS three-year study have been published in Epilepsia1.

Several CORE-VNS study findings were highlighted in the recent article on GTC seizures in DRE patients who received VNS Therapy™, including:

• At 12 months, the median reduction in GTC seizure frequency was 74%, and this reduction was sustained through 24 months with a median reduction increasing to 77%.
• Freedom from GTC seizures (defined as the absence of GTC seizures in the three months prior to the study visit) was reported by 37% and 43% of people at the 12- and 24-month study visits, respectively, despite people having a median 10-year duration of epilepsy.
• Approximately half of those experiencing GTC seizures were under 18 years of age, and nearly all (94%) had no history of any other previous surgery for epilepsy.
• GTC seizure reduction was seen early, with a median 52% reduction in GTC seizure frequency at the three-month study visit.

The CORE-VNS study evaluated comprehensive outcomes of real-world evidence for more than 800 epilepsy patients treated with VNS Therapy worldwide. The 115 people with drug-resistant epilepsy and generalized seizures at baseline in this analysis had a median of 10 years between epilepsy diagnosis and VNS Therapy implantation. Additionally, 90% of this participant population were under 18 years of age at the time of diagnosis.